Current stock page

Financial Data

BMY Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Sep 4, 2026

BMY

Financial Data
Bristol-Myers Squibb Company
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 9/10
Leader
Strong Relative Position
Score data as of Sep 4, 2026
Last price
$66.82
-$1.27 (-1.87%)
Latest market quote
Momentum69
Value65
Quality71
Risk Resilience48
Sentiment50
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 7, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$12.97B$11.49B$12.5B$12.22B$12.27B$11.2B$12.34B$11.89B
Gross Profit$9.25B$8.07B$8.41B$8.79B$8.07B$7.34B$7.42B$6.62B
Operating Income
Net Income$3.32B$2.68B$1.09B$2.2B$1.31B$2.46B$72M$1.21B
EPS$1.62$1.31$0.53$1.08$0.64$1.21$0.04$0.6
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$3.39B$1.1B$1.97B$6.31B$3.92B$1.95B$4.44B$5.59B
Capital Expenditure-$305M-$347M-$370M-$320M-$361M-$260M-$378M-$324M
Free Cash Flow$3.09B$757M$1.6B$5.99B$3.56B$1.69B$4.06B$5.27B
Net Cash Provided By Operating Activities$3.39B$1.1B$1.97B$6.31B$3.92B$1.95B$4.44B$5.59B
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$87.63B$86.48B$10.67B$96.89B$94.68B$92.43B$92.6B$93.67B
Total Debt$43.12B$46.51B-$45.11B$51.17B$51.09B$51.41B$51.37B$51.57B
Cash And Cash Equivalents
Total Liabilities$65.32B$66.37B-$45.11B$78.29B$77.19B$74.98B$76.22B$76.47B
Total Stockholders Equity$22.32B$20.1B$55.78B$18.6B$17.49B$17.45B$16.39B$17.2B
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio8.8911.5725.3410.4417.9812.61398.4821.66
P/B ratio5.276.181.974.955.47.127.036.12
P/S ratio9.0710.798.817.527.6811.069.38.82
Debt To Equity1.932.31-0.812.752.922.953.133
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio5.276.181.974.955.47.127.036.12
P/S ratio9.0710.798.817.527.6811.069.38.82
Return On Equity14.86%13.34%1.95%11.86%7.51%14.12%0.44%7.06%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
14.74
multipleSep 4, 2026
Pb
6.12
multipleSep 4, 2026
Revenue Growth Yoy
12.92
percentSep 4, 2026
EPS Growth Yoy
23.66
percentSep 4, 2026
Gross Margin
70.16
percentSep 4, 2026
Operating Margin
28.27
percentSep 4, 2026
ROE
46.75
percentSep 4, 2026
ROIC
15.47
percentSep 4, 2026
Debt To Equity
1.93
ratioSep 4, 2026
FCF Yield
8.37
percentSep 4, 2026
Technical indicators
Close
66.82
priceSep 4, 2026
Volume
4,825,447
volumeSep 4, 2026
Rsi14
59.37
indexSep 4, 2026
MACD
1.26
indexSep 4, 2026
MACD Signal
1.41
indexSep 4, 2026
MACD Histogram
-0.15
indexSep 4, 2026
Adx14
40.01
indexSep 4, 2026
Sma50
62.9
priceSep 4, 2026
Sma200
58.14
priceSep 4, 2026
Atr14
1.51
priceSep 4, 2026
Historical Volatility
0.24
percentSep 4, 2026
Volume Ma20
8,127,558.75
volumeSep 4, 2026
Risk measures
Resilience Score
48
score_0_100Sep 4, 2026
Beta
0.23
ratioSep 4, 2026
Volatility Annual
27.58
percentSep 4, 2026
Max Drawdown
-13.42
percentSep 4, 2026
Sharpe Ratio
1.3
ratioSep 4, 2026
Var95
-2.51
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BMY Financial Data FAQ

What is Bristol-Myers Squibb Company's revenue?

Bristol-Myers Squibb Company's revenue is one of the core financial data points for BMY. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Bristol-Myers Squibb Company's revenue growing?

Revenue growth shows whether Bristol-Myers Squibb Company is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BMY's EPS?

BMY's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Bristol-Myers Squibb Company's net income?

Bristol-Myers Squibb Company's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Bristol-Myers Squibb Company generate?

Free cash flow shows how much cash Bristol-Myers Squibb Company generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Bristol-Myers Squibb Company have?

Cash and debt help frame BMY's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.